Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey

PURPOSE: The evolving epidemiology and treatment landscape of COVID-19 necessitates research into potential drug-drug interactions (pDDIs) from the use of new treatments for COVID-19, particularly those that contain ritonavir, a potent inhibitor of the cytochrome P350 3A4 (CYP3A4) metabolic pathway....

Descripción completa

Detalles Bibliográficos
Autores principales: Igho-Osagie, Ebuwa, Brzozowski, Kaylen, Jin, Harry, Brown, Jeffrey, Williams, Marissa Grifasi, Puenpatom, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036307/
https://www.ncbi.nlm.nih.gov/pubmed/37032225
http://dx.doi.org/10.1016/j.clinthera.2023.03.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036307/
https://www.ncbi.nlm.nih.gov/pubmed/37032225
http://dx.doi.org/10.1016/j.clinthera.2023.03.012

Ejemplares similares